Loading…
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $6M | $79M | $71M | $-84M | 44.7% | - | -211.7% |
| 2024 | $0M | $-57M | $-64M | $-58M | -144.7% | -100.0% | 17.6% |
| 2023 | $4M | $-51M | $-54M | $-37M | -365.5% | 147.5% | 36.5% |
| 2022 | $1M | $-34M | $-40M | $-44M | -148.3% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 1.41 | 3.50 | 0 | 5.82 |
| Operating Revenue | - | 1.41 | 3.50 | 0 | 3.40 |
| Cost Of Revenue | - | 0.45 | 1.60 | 0 | 3.42 |
| Gross Profit | - | 0.96 | 1.90 | 0 | 2.40 |
| Operating Expense | - | 46.22 | 50.10 | 64.21 | 91.84 |
| Research And Development | - | 28.96 | 31.09 | 34.36 | 26.81 |
| Selling General And Administration | - | 17.26 | 19 | 29.85 | 65.03 |
| Total Expenses | - | 46.67 | 51.70 | 64.21 | 95.27 |
| Operating Income | - | -45.26 | -48.20 | -64.21 | -89.45 |
| Total Operating Income As Reported | - | -50.92 | -47.14 | -64.21 | -89.45 |
| EBITDA | - | -34.38 | -50.57 | -56.62 | 78.59 |
| Normalized EBITDA | - | -40.11 | -39.94 | -55.86 | 72.45 |
| EBIT | - | -38.96 | -53.77 | -59.53 | 75.02 |
| Interest Income | - | 0.43 | 2.12 | 4.25 | 5.56 |
| Interest Expense | - | 0.74 | 0.42 | 4.21 | 3.74 |
| Net Interest Income | - | -0.30 | 1.70 | 0.04 | 1.82 |
| Other Non Operating Income Expenses | - | 0.14 | 2.94 | 1.19 | 152.78 |
| Other Income Expense | - | 5.87 | -7.69 | 0.44 | 158.92 |
| Interest Income Non Operating | - | 0.43 | 2.12 | 4.25 | 5.56 |
| Interest Expense Non Operating | - | 0.74 | 0.42 | 4.21 | 3.74 |
| Net Non Operating Interest Income Expense | - | -0.30 | 1.70 | 0.04 | 1.82 |
| Pretax Income | - | -39.70 | -54.19 | -63.73 | 71.28 |
| Tax Provision | - | - | - | 0 | 0.10 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0.01 |
| Net Income Continuous Operations | - | -39.70 | -54.19 | -63.73 | 71.18 |
| Net Income From Continuing And Discontinued Operation | - | -39.70 | -54.19 | -63.73 | 71.18 |
| Net Income From Continuing Operation Net Minority Interest | - | -39.70 | -54.19 | -63.73 | 71.18 |
| Net Income | - | -39.70 | -54.19 | -63.73 | 71.18 |
| Net Income Common Stockholders | - | -43.48 | -54.19 | -63.73 | 71.18 |
| Net Income Including Noncontrolling Interests | - | -39.70 | -54.19 | -63.73 | 71.18 |
| Normalized Income | - | -45.42 | -43.56 | -62.98 | 65.05 |
| Diluted NI Availto Com Stockholders | - | -43.48 | -54.19 | -63.73 | 71.18 |
| Basic Average Shares | - | 7.86 | 21.38 | 41.05 | 52.95 |
| Diluted Average Shares | - | 7.86 | 21.38 | 41.05 | 66.14 |
| Reconciled Depreciation | - | 4.58 | 3.20 | 2.91 | 3.56 |
| Reconciled Cost Of Revenue | - | 0.45 | 1.60 | 0 | 3.42 |
| Total Unusual Items | - | 5.72 | -10.63 | -0.76 | 6.14 |
| Total Unusual Items Excluding Goodwill | - | 5.72 | -10.63 | -0.76 | 6.14 |
| Preferred Stock Dividends | - | 3.78 | - | - | - |
| Special Income Charges | -23.96 | -5.66 | 1.06 | 0 | - |
| Other Special Charges | -8.50 | - | - | - | - |
| Impairment Of Capital Assets | 32.47 | 3.15 | 0 | - | - |
| Gain On Sale Of Security | - | 11.38 | -11.70 | -0.76 | 6.14 |
| Depreciation Amortization Depletion Income Statement | 3.25 | - | - | - | - |
| Depreciation And Amortization In Income Statement | 3.25 | - | - | - | - |
| General And Administrative Expense | - | 17.26 | 19 | 29.85 | 65.03 |
| Other Gand A | - | 17.26 | 19 | 29.85 | 65.03 |
| Gain On Sale Of Ppe | - | -2.51 | 1.06 | 0 | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Abeona Therapeutics Inc.this co. | ABEO | $332M | 4.66 | 2.08 | 44.7% | 3.54 |
| Larimar Therapeutics, Inc. | LRMR | $342M | - | 4.38 | -212.2% | - |
| Enanta Pharmaceuticals, Inc. | ENTA | $341M | -4.17 | 5.27 | -126.5% | -5.14 |
| Verastem, Inc. | VSTM | $339M | -1.62 | 5.93 | -366.2% | -1.07 |
| Simulations Plus, Inc. | SLP | $336M |
| - |
| - |
| - |
| - |
| - |
| -5.20 |
| 2.70 |
| -51.9% |
| 20.82 |
| 908 Devices Inc. | MASS | $334M | 17.11 | 2.32 | 13.6% | -12.61 |
| Humacyte, Inc. | HUMA | $331M | -8.10 | 106.40 | -1313.4% | -15.52 |
| Organogenesis Holdings Inc. | ORGO | $319M | 8.62 | 1.06 | 12.3% | 3.71 |
| Rocket Pharmaceuticals, Inc. | RCKT | $319M | -1.43 | 1.15 | -80.5% | -1.27 |
| Peer Median | - | -1.62 | 3.54 | -103.5% | -1.27 | |